 SALT LAKE CITY, June 14, 2021 PRNewswire -- Lipocine Inc. Nasdaq: LPCN, a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration FDA has cleared the Companys Investigational New Drug Application IND to initiate a Phase 2 study to evaluate the therapeutic potential of LPCN 1154, an oral neuro-steroid product candidate, for the treatment of postpartum depression PPD in adults. A pharmacokinetic PK study to assess dose proportionality is planned to start in July 2021 with top-line results expected in the third quarter of 2021. 